ZSCAN18 and breast cancer: Although there was no significant difference in post-progression survival (PPS) between the high and low expression groups, ZSCAN18 was positively correlated with distant metastasis-free survival (DMFS) in BC (HR = 0.65; 95% CI = 0.54–0.78; p = 2.6E-06, < 0.001, Figures 3C, D).